Agios Pharmaceuticals (AGIO) Insider Smith Buys 2,816 Shares

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

Cynthia Smith bought 2,816 shares of Agios Pharmaceuticals, Inc. (AGIO) on June 18, 2026. The purchase is valued at about $99,000, based on the stock's price of $35.47 at the time. This trade is part of a larger trend of insider buying at the company, which may indicate confidence in Agios's future prospects.

Other Insiders Join the Buying Spree

On the same day as Smith's purchase, several other insiders also bought shares of Agios Pharmaceuticals. Sarah Gheuens, the Chief Medical Officer, acquired 3,000 shares. Additionally, executives Rahul Ballal, Jay Backstrom, David Scadden, and Jacqualyn Fouse each purchased 14,950 shares. This collective buying activity suggests a strong belief in the company's direction.

Stock Performance and Market Context

Agios Pharmaceuticals has shown some volatility, with shares trading between $22.24 and $46.00 over the past year. Currently, the stock is priced at $35.47, which is near its 50-day moving average of $34.43. The recent insider purchases come as analysts maintain a generally positive outlook on the stock, with a consensus price target of $46.25. This suggests that the shares may have room to grow based on the analysts' expectations.

Analysts Set New Price Targets

Analysts have expressed a favorable view of Agios Pharmaceuticals. On October 7, 2026, Truist Securities maintained a "Buy" rating with a price target of $37.00. Similarly, B of A Securities also kept its "Buy" rating but raised its target to $50.00 on September 21, 2026. Other firms, like Citigroup and JP Morgan, have maintained their ratings, indicating confidence in the company's strategies and potential.

What Agios Pharmaceuticals, Inc. Does

Agios Pharmaceuticals, Inc., based in Cambridge, Massachusetts, focuses on developing innovative therapies for diseases related to cellular metabolism. Its lead product, PYRUKYND, is used for treating hemolytic anemias and is currently in clinical trials for other conditions. The recent insider activity adds to the narrative of a company poised for growth in the biotechnology sector.

What's Ahead for Agios Pharmaceuticals, Inc.

Investors will be watching Agios Pharmaceuticals closely as it approaches its next earnings report on October 29, 2026. The recent insider buying activity could provide insights into management's confidence in upcoming results. It's important to note that these filings reflect past actions and may not indicate current positions.